The impact of increased pretreatment serum sIL-5Rα levels on efficacy of anti-IL-5 treatment has only been assessed in one study evaluating reslizumab in CRSwNP, showing no relationship (50). The gene discussed is IL5; the disease is chronic rhinosinusitis with nasal polyps.